Suspended

IRAP-IRAssessement of the Diagnostic Interest in Insulin Resistance of the Specific and Quantitative ELISA Assay of a Plasma Biomarker of Cellular Glucose Capture: the Secreted IRAP Protein (Regulated Amino Peptidase Insulin)

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Dosage of IRAP during OGTT

Diagnostic Test
Who is being recruted

Hyperinsulinism+3

+ Insulin Resistance

+ Metabolic Diseases

From 40 to 65 Years
+14 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Diagnostic Study

Interventional
Study Start: September 2020
See protocol details

Summary

Principal SponsorUniversity Hospital, Grenoble
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: September 14, 2020

Actual date on which the first participant was enrolled.

This study consists of two visits, from three to fifteen days apart. Patients with different levels of insulin resistance will be enrolled in this study. The level of insulin resistance will be estimated with a hyperinsulinemic euglycemic clamp that will be performed at the second visit. The first visit : * Subjects will be on an empty stomach * A blood test including HbA1C, C-Peptid, lipid profile, creatinine,urea, hepatic workup * An oral glucose tolerance test (OGTT) of 3 hours will be performed. Blood samples will be taken two time (T-15', T0) 15 minutes apart at Baseline (before taking the glucose). And then after the glucose intake, blood sample will be taken every 15 minutes (T15', T30', T 45', T60', T75', T90', T105', T120' and 180') to measure insulinemia, blood sugar, and IRAP concentration. The second visit includes a 3-hours hyperinsulinemic euglycemic clamp.

Official TitleAssessement of the Diagnostic Interest in Insulin Resistance of the Specific and Quantitative ELISA Assay of a Plasma Biomarker of Cellular Glucose Capture: the Secreted IRAP Protein (Regulated Amino Peptidase Insulin)
NCT04028895
Principal SponsorUniversity Hospital, Grenoble
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

21 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Diagnostic Study

Diagnostic studies focus on improving how we detect or confirm a disease. They test new tools or techniques that could provide faster or more accurate diagnoses.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 40 to 65 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

HyperinsulinismInsulin ResistanceMetabolic DiseasesNutritional and Metabolic DiseasesMetabolic SyndromeGlucose Metabolism Disorders

Criteria

4 inclusion criteria required to participate
Patient without known diabetes

Abdominal perimeter greater than 80 cm for women and greater than 94 cm for men

Patient affiliated to social security insurance or beneficiary of social security insurance.

Signed consent

10 exclusion criteria prevent from participating
Consumption of narcotic

Medication that may interfere with glucose metabolism

History of bariatric surgery

Known acute or chronic renal insufficiency

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 4 locations

Suspended

Service de Nutrition clinique et CRNH Auvergne

Clermont-Ferrand, FranceOpen Service de Nutrition clinique et CRNH Auvergne in Google Maps
Suspended

Inserm CIC1406, clinical research center, Grenoble Alpes university hospital

Grenoble, France
Suspended

CRNH Rhône-Alpes et Centre Hospitalier LYON Sud

Lyon, France
Suspended

Endocrinologie-Diabétologie-Nutrition et CIC, CHU DE MONTPELLIER

Montpellier, France
Suspended4 Study Centers